Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBATBIL: Atezolizumab + Bevacizumab + mFOLFOX6 in Advanced BTC
NCT05052099Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Oct 2021
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in biliary tract cancer (BTC), sponsored by Universitätsmedizin Essen. Primary endpoint: Overall Response Rate at 12 weeks. Started Oct 2021; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05052099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05052099.